tsRNA-GlyGCC promotes colorectal cancer progression and 5-FU resistance by regulating SPIB.

Rong XuAshuai DuXinpei DengWei DuKaiying ZhangJianbo LiYingxue LuXiaoli WeiQinglong YangXiaoming Xie

Published in: Journal of experimental & clinical cancer research : CR (2024)

Our study revealed a specific tsRNA-GlyGCC-engaged pathway in CRC progression. Targeting tsRNA-GlyGCC in combination with 5-FU may provide a promising nanotherapeutic strategy for the treatment of 5-FU-resistance CRC.

Keyphrases

cancer therapy
drug delivery
combination therapy